Keyword → ABBV

FDA's Vinay Prasad to Exit Biologics Post in April, Sending Biotech Stocks Sharply Higher

The announced departure of Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, triggered a significant rally in biotech equities Monday, with uniQure surging more than 31% in premarket trading. Investors interpreted the news as a signal that the agency may adopt a more predictable and industry-friendly regulatory posture for vaccines, gene therapies, and rare disease treatments.

Wall Street Volatility Spikes as Stagflation Fears Grip Investors

Markets are grappling with a potentially dangerous combination of slowing economic growth and rising energy costs. Investors are increasingly worried that the U.S. economy could face stagflation, a scenario where inflation remains elevated even as growth weakens. The outlook has triggered sharp moves across equities, commodities and bond markets as traders reposition portfolios to navigate an uncertain macroeconomic environment.

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major CAR-T Cell Therapy Bet

Gilead Sciences announced Monday it will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share, representing an implied equity value of $7.8 billion and an 87% premium to Arcellx's Friday closing price. The deal centers on anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma that has already received FDA acceptance of its Biologics License Application, with a regulatory decision expected by December 23, 2026.

Tax Foundation Report Confirms Tariffs as Largest Tax Hike Since 1993, Weighing on 2026 Outlook

A comprehensive analysis released today by the Tax Foundation reveals that the cumulative impact of recent US tariffs represents the largest tax increase as a share of GDP in over three decades. The report estimates an average annual burden of $1,300 per US household in 2026, with businesses and consumers bearing nearly 90% of the costs. This structural drag is increasingly reflected in the downward revision of earnings guidance across the industrial, consumer discretionary, and healthcare sectors.

Philips Reports 2025 Results With Margin Expansion and 2026 Outlook Targets

Royal Philips published its full-year 2025 financial results, highlighting accelerated growth, expanding profit margins and robust cash flow. The company also unveiled strategic targets for 2026-2028, emphasizing innovation and operational efficiency across health technology segments.